New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For MDT;COV;INTC;BSX;VRTX;JNJ From The Last 14 Days
Check below for free stories on MDT;COV;INTC;BSX;VRTX;JNJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
September 15, 2014
16:08 EDTBSXBoston Scientific says REPRISE II data show sustained safety, performance
New data from the Boston Scientific clinical trial program of the LotusValve System continue to demonstrate strong performance as a less invasive treatment for patients with severe aortic stenosis who are considered high risk for surgical valve replacement. Data from the REPRISE II clinical trial confirmed safety and effectiveness out to one year, with more than 86% of patients exhibiting a complete absence of paravalvular aortic regurgitation and no patients demonstrating moderate or severe paravalvular aortic regurgitation. New data from the REPRISE I and REPRISE II clinical trials were presented at the 26th Transcatheter Cardiovascular Therapeutics meeting, the annual scientific symposium of the Cardiovascular Research Foundation. REPRISE II is an ongoing prospective, single-arm, multi-center study designed to evaluate safety and performance of the Lotus Valve System for symptomatic patients with severe calcific aortic stenosis who are considered high risk for surgical valve replacement. The study enrolled 120 patients at 14 sites in Australia, France, Germany and the UK. In REPRISE II, key one-year results include the following: Mean aortic valve pressure gradient remained low and stable at 12.6 + 5.7 mmHg. More than 86% of patients had no paravalvular aortic regurgitation by independent core lab assessment. In addition, no cases of moderate or severe paravalvular aortic regurgitation occurred. Mild and trace paravalvular aortic regurgitation rates were low at 11.4 and 2.3%, respectively. Cardiovascular mortality rate was 6.7%. Disabling stroke rate was 3.4%. No cases of non-study valve implantation, unplanned use of cardiopulmonary bypass, valve embolization, valve-in-valve or ectopic valve placement occurred.
08:06 EDTMDTMedtronic announces SEEQ wearable cardiac monitoring system in U.S.
Subscribe for More Information
07:45 EDTMDT, BSXCardiovascular Research Foundation to hold a conference
Transcatheter Cardiovascular Therapeutics: TCT 2014 to be held in Washington, D.C. on September 13-17 with some presentations being webcasted. Webcast Link
07:27 EDTJNJIBC Life Sciences to hold a conference
Subscribe for More Information
07:21 EDTMDTHeart Failure Society of America to hold annual meeting
Subscribe for More Information
07:19 EDTINTCSNIA to hold a conference
Subscribe for More Information
07:04 EDTCOVCovidien announces start of enrollment in two neurovascular trials
Covidien announced the start of enrollment in two clinical trials designed to further underscore the safety and effectiveness of the company’s advanced neurovascular solutions. Baptist Medical Center in Jacksonville, Florida, treated the first patient enrolled in the PREMIER Prospective study, an international Investigational Device Exemption clinical study to evaluate the Pipeline embolization device in smaller unruptured intracranial aneurysms. Separately, Baptist Health Lexington in Kentucky, enrolled the first patient in the STRATIS Registry for Endovascular Stroke Devices, which will evaluate the use of all Covidien market-released stroke devices. The PREMIER study will enroll up to 141 patients in 20 global sites and is designed to assess the safety and effectiveness of the Pipeline device in the treatment of unruptured, small and medium wide-necked intracranial aneurysms. The STRATIS Registry, a prospective, multi-center, non-randomized, observational registry designed to evaluate the use of Covidien endovascular stroke devices in patients diagnosed with an acute ischemic stroke. Covidien’s current endovascular stroke device in the U.S. is the Solitaire™ 2 revascularization device. As many as 60 U.S. sites are expected to participate in the STRATIS Registry, which will enroll up to 1,000 patients to collect clinical outcomes for interventional stroke patients in a real world setting.
September 13, 2014
16:47 EDTMDTMedtronic CoreValve provides positive outcomes out two years in risky patients
Medtronic announced new data showing that transcatheter aortic valve replacement, TAVR, with the CoreValve System continued to provide safe and effective treatment, while maintaining exceptional rates of survival out to two years for patients who were considered too ill or frail to have their aortic valves replaced through traditional open-heart surgery. Without treatment, these patients had a 50% chance of death at one year.
September 12, 2014
15:03 EDTMDT, BSXSt. Jude Medical pausing Portico sales, implants, says Wells Fargo
Subscribe for More Information
September 11, 2014
13:51 EDTINTCIntel tablet AP shipments could reach 7M units in 2H14, Digitimes reports
In the first half of 2014, Intel shipped approximately 1.5M tablet application processors, but Digitimes Research expects the company's shipments to total 7M units in the second half due to China brand vendors' and white-box players' full support, Digitimes reports. Reference Link
10:00 EDTMDTOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Airgas (ARG) initiated with a Neutral at Northcoast... CBOE Holdings (CBOE) initiated with a Buy at Deutsche Bank... CME Group (CME) initiated with a Buy at Deutsche Bank... Colfax (CFX) initiated with a Neutral at Northcoast... Corporate Office Properties (OFC) initiated with an Overweight at Capital One... Edwards Lifesciences (EW) initiated with a Buy at Sterne Agee... Energen (EGN) initiated with a Buy at Deutsche Bank... Goodrich Petroleum (GDP) initiated with an Outperform at Cowen... GreenHunter Resources (GRH) initiated with a Hold at Stifel... GrubHub (GRUB) initiated with a Market Perform at Barrington... Illinois Tool Works (ITW) initiated with a Neutral at Northcoast... IntercontinentalExchange (ICE) initiated with a Hold at Deutsche Bank... JD.com (JD) initiated with a Buy at Brean Capital... Lincoln Electric (LECO) initiated with a Buy at Northcoast... Live Nation (LYV) initiated with a Buy at Jefferies... Medtronic (MDT) initiated with a Neutral at Sterne Agee... Midstates Petroleum (MPO) initiated with a Market Perform at Cowen... NASDAQ (NDAQ) initiated with a Hold at Deutsche Bank... Newfield Exploration (NFX) initiated with an Outperform at Iberia... Newpark Resources (NR) initiated with an Outperform at Credit Suisse... Nuverra Environmental (NES) initiated with a Buy at Stifel... Palo Alto (PANW) initiated with a Buy at Roth Capital... Petrobras (PBR) initiated with an Outperform at Cowen... RSP Permian (RSPP) initiated with a Hold at Deutsche Bank... Sensata (ST) initiated with an Equal Weight at Morgan Stanley... Stage Stores (SSI) initiated with a Neutral at Credit Suisse... Synergy Resources (SYRG) initiated with an Outperform at Cowen... TE Connectivity (TEL) initiated with an Overweight at Morgan Stanley... Twitter (TWTR) initiated with a Buy at Canaccord... Walter Investment (WAC) initiated with an Underweight at Barclays... Washington REIT (WRE) initiated with an Equalweight at Capital One... Yandex (YNDX) initiated with a Buy at Canaccord... Yara International (YARIY) initiated with a Neutral at Credit Suisse.
08:11 EDTMDTMedtronic Noncompliant Balloon Dilatation Catheter receives FDA clearance
Medtronic announced the FDA 510(k) clearance and launch of the NC Euphora Noncompliant Balloon Dilatation Catheter. Following drug-eluting stent implantation to reopen a narrowed artery, a noncompliant balloon is inflated with high pressure to ensure that the stent is fully apposed in order to facilitate transfer of the drug to the artery wall. Stent under-expansion has been defined as a major risk factor for both artery re-narrowing, or restenosis, and the potential formation of blood clots, known as stent thrombosis. Postdilatation with noncompliant balloons has been recommended to overcome these complications and provide optimal stent expansion after stent placement.
07:35 EDTINTCAntitrust suit over tech giants' hiring pushed back, WSJ reports
Subscribe for More Information
07:11 EDTJNJMedivation price target raised to $112 from $89 at Stifel
Subscribe for More Information
September 10, 2014
16:09 EDTMDTMedtronic initiated with a Neutral at Sterne Agee
Target $68.
16:00 EDTINTCIntel acquires Powerwave patent portfolio
Subscribe for More Information
10:14 EDTJNJJohnson & Johnson says off to 'very good start' this year
Subscribe for More Information
09:32 EDTMDTMedtronic announces first U.S. implants in CoreValve Evolut R study
Subscribe for More Information
09:27 EDTVRTXVertex shares likely to advance further, says RBC Capital
Subscribe for More Information
07:37 EDTINTCIntel products look strong, says Wells Fargo
Subscribe for More Information
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use